China’s 1st Original ARNI Antihypertensive, XinChaoTuo®, launched Online on China
Source: Dengyuemed | August 21, 2025 | Category: Pharmaceuticals
Recently, the new antihypertensive drug XinchaoTuo® (Sacubitril/Aliasartan Calcium Tablets) was officially launched online through Hong Kong DengYueMedicine.
Developed independently by Shenzhen Salubris Pharmaceuticals, this product is China’s first original ARNI (angiotensin receptor neprilysin inhibitor) class antihypertensive medication, offering safer and more effective blood pressure control.
Leveraging its position as the “No.1 online healthcare entry point,” China Drug Import and Export Wholesaler will rely on its omni-channel supply chain and integrated healthcare services to bring patients a new treatment option.
Hypertension is one of the most common chronic diseases in China, yet the control rate remains low. According to the Chinese Hypertension Prevention and Control Guidelines, the control rate of adult hypertension in China is only 16.8%.
This challenge is partly due to patients’ lack of awareness, as well as limited treatment options and poor adherence to antihypertensive therapy.
In recent years, deeper research into hypertension and its complications has paved the way for new treatment strategies and innovative antihypertensive drugs.
Compared with traditional medications, ARNI drugs offer a dual mechanism of blood pressure reduction: on one hand, inhibiting neprilysin prevents the degradation of natriuretic peptides, producing diuretic, natriuretic, and vasodilatory effects; on the other, blocking angiotensin receptors prevents the compensatory activation of the RAS system.
Clinical evidence shows that ARNI therapy significantly reduces both office and 24-hour ambulatory blood pressure in resistant hypertension patients, improving success rates.
The latest Chinese Hypertension Guidelines now recommend ARNI as a first-line and maintenance antihypertensive option.
As China’s first self-developed ARNI, XinchaoTuo® overcame technical barriers in co-crystal drug development and became the world’s second ARNI co-crystal medication.
Its innovative design ensures synchronized peak plasma levels of sacubitril’s active metabolite and aliasartan, while prolonging the half-life of aliasartan, resulting in more stable effects.
Importantly, ARNI drugs not only provide strong blood pressure reduction but also demonstrate cardio-renal protection, making them particularly suitable for patients with hypertension complicated by heart failure or chronic kidney disease.
A spokesperson from Salubris Pharmaceuticals stated that hypertension is one of the company’s core therapeutic areas.
In addition to XinchaoTuo®, Salubris has developed a full portfolio of antihypertensive products, ranging from monotherapy to fixed-dose combinations, including the ARB monotherapy Xintan® (Azilsartan Ester Tablets), and combination tablets such as FuliTan® (Azilsartan/Amlodipine Tablets) and FuLiAn® (Azilsartan/Indapamide SR Tablets).
A China Medicine Wholesaler representative noted: “Hong Kong Deng Yue Medicine is committed to delivering high-quality medical and healthcare products to consumers. Through this collaboration with Salubris, we will accelerate access to XinchaoTuo®, enabling this innovative domestic antihypertensive drug to reach a wider patient population and jointly improve China’s hypertension management level.”
In recent years, Hong Kong Pharmaceutical Distributor has strengthened its role as the leading platform for launching innovative medicines.
Many cutting-edge antihypertensive and specialty drugs have been introduced through the Hong Kong Drug Wholesale Distributor, helping patients access more precise and effective treatments.
Moving forward, Pharmaceutical Distributor China will continue to collaborate with global pharmaceutical partners to enhance the accessibility of new therapies and help more patients receive scientifically and effectively care.
